This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Francia, G. Articles by Kerbel, R. S. Search for Related Content PubMed PubMed Citation Articles by Francia, G. Articles by Kerbel, R. S.

Molecular and Cellular Biology Research, Sunnybrook and Women's College Health Sciences Centre and Medical Biophysics, University of Toronto, Toronto, Ontario, Canada

Requests for reprints: Robert S. Kerbel, Molecular and Cellular Biology Research, Sunnybrook and Women's College Health Sciences Centre, S-217 Research Building, 2075 Bayview Avenue, Toronto, Ontario, Canada M4N 3M5. Phone: 416-480-5711; Fax: 416-480-5703. E-mail: kerbel{at}srcl.sunnybrook.utoronto.ca

Similar to other anticancer agents, intrinsic or acquired resistance to DNA-damaging chemotherapeutics is a major obstacle for cancer therapy. Current strategies aimed at overcoming this problem are mostly based on the premise that tumor cells acquire heritable genetic mutations that contribute to drug resistance. Here, we present evidence for an epigenetic, tumor cell adhesion–mediated, and reversible form of drug resistance that is associated with a reduction of DNA mismatch repair proteins PMS2 and/or MLH1 as well as other members of this DNA repair process. Growth of human breast cancer, human melanoma, and murine EMT-6 breast cancer cell lines as multicellular spheroids in vitro, which is associated with increased resistance to many chemotherapeutic drugs, including alkylating agents, is shown to lead to a reproducible down-regulation of PMS2, MLH1, or, in some cases, both as well as MHS6, MSH3, and MSH2. The observed down-regulation is in part reversible by treatment of tumor spheroids with the DNA-demethylating agent, 5-azacytidine. Thus, treatment of EMT-6 mouse mammary carcinoma spheroids with 5-azacytidine resulted in reduced and/or disrupted cell-cell adhesion, which in turn sensitized tumor spheroids to cisplatin-mediated killing in vitro. Our results suggest that antiadhesive agents might sensitize tumor spheroids to alkylating agents in part by reversing or preventing reduced DNA mismatch repair activity and that the chemosensitization properties of 5-azacytidine may conceivably reflect its role as a potential antiadhesive agent as well as reversal agent for MLH1 gene silencing in human tumors.

The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked advertisement in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

Received 8/20/04; revised 6/30/05; accepted 8/10/05.

This article has been cited by other articles:

				F. J. Rodriguez-Jimenez, V. Moreno-Manzano, R. Lucas-Dominguez, and J.-M. Sanchez-Puelles Hypoxia Causes Downregulation of Mismatch Repair System and Genomic Instability in Stem Cells Stem Cells, August 1, 2008; 26(8): 2052 - 2062. [Abstract] [Full Text] [PDF]

				V. F. Chekhun, N. Y. Lukyanova, O. Kovalchuk, V. P. Tryndyak, and I. P. Pogribny Epigenetic profiling of multidrug-resistant human MCF-7 breast adenocarcinoma cells reveals novel hyper- and hypomethylated targets Mol. Cancer Ther., March 1, 2007; 6(3): 1089 - 1098. [Abstract] [Full Text] [PDF]

				M. D. Onken, J. P. Ehlers, L. A. Worley, J. Makita, Y. Yokota, and J. W. Harbour Functional Gene Expression Analysis Uncovers Phenotypic Switch in Aggressive Uveal Melanomas. Cancer Res., May 1, 2006; 66(9): 4602 - 4609. [Abstract] [Full Text] [PDF]